Biofrontera Company Top Insiders

BFRI Stock  USD 0.87  0.11  14.47%   
Biofrontera employs about 83 people. The company is managed by 10 executives with a total tenure of roughly 194 years, averaging almost 19.0 years of service per executive, having 8.3 employees per reported executive. Assessment of Biofrontera's management performance can provide insight into the firm performance.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.

Biofrontera Management Team Effectiveness

The company has return on total asset (ROA) of (0.4024) % which means that it has lost $0.4024 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4941) %, meaning that it created substantial loss on money invested by shareholders. Biofrontera's management efficiency ratios could be used to measure how well Biofrontera manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.84. The Biofrontera's current Return On Capital Employed is estimated to increase to -2.19. As of now, Biofrontera's Total Current Assets are increasing as compared to previous years. The Biofrontera's current Intangible Assets is estimated to increase to about 2.8 M, while Non Currrent Assets Other are projected to decrease to under 457.9 K.
The current Common Stock Shares Outstanding is estimated to decrease to about 1 M. The current Net Loss is estimated to decrease to about (772.8 K)

Biofrontera Workforce Comparison

Biofrontera is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 6,374. Biofrontera claims roughly 83.0 in number of employees contributing just under 2% to equities under Health Care industry.

Biofrontera Profit Margins

The company has Profit Margin (PM) of (0.38) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.65) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.65.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.540.488
Significantly Up
Slightly volatile

Biofrontera Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biofrontera insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biofrontera's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biofrontera insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Biofrontera Notable Stakeholders

A Biofrontera stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biofrontera often face trade-offs trying to please all of them. Biofrontera's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biofrontera's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Hermann LuebbertPresident CEOProfile
Daniel JDGeneral ComplianceProfile
Jon MBAVice AffairsProfile
Erica CPACOO, CEOProfile
Jeff HolmHead DevelProfile
Mark BaldygaHead MarketingProfile
Alycia TorresVice AdministrationProfile
Samantha WiddicombeSenior CommunicationsProfile
Eugene IIIChief OfficerProfile
Hermann LubbertEx PresProfile

About Biofrontera Management Performance

The success or failure of an entity such as Biofrontera often depends on how effective the management is. Biofrontera management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biofrontera management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biofrontera management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.80)(0.84)
Return On Capital Employed(2.30)(2.19)
Return On Assets(0.72)(0.76)
Return On Equity(4.20)(3.99)

Biofrontera Workforce Analysis

Traditionally, organizations such as Biofrontera use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biofrontera within its industry.

Biofrontera Manpower Efficiency

Return on Biofrontera Manpower

Revenue Per Employee410.5K
Revenue Per Executive3.4M
Net Loss Per Employee242.5K
Net Loss Per Executive2M
Working Capital Per Employee60.1K
Working Capital Per Executive498.7K

Complementary Tools for Biofrontera Stock analysis

When running Biofrontera's price analysis, check to measure Biofrontera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera is operating at the current time. Most of Biofrontera's value examination focuses on studying past and present price action to predict the probability of Biofrontera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera's price. Additionally, you may evaluate how the addition of Biofrontera to your portfolios can decrease your overall portfolio volatility.
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments